JAK1 and melanoma: 3pRNA treatment even forced de novo HLA-I APM expression in patient-derived JAK1 mutant melanoma cells and restored their T cell sensitivity, demonstrating that activated RIG-I triggered an IFN-independent salvage pathway capable of overcoming tumor cell-intrinsic T cell resistance.